CAR T-Cell Therapy: How It Works, Eligibility, and Side Effects

CAR T-cell therapy is an advanced form of immunotherapy that uses a patient’s own immune cells to recognize and attack certain cancers, especially some blood cancers. It can be an important option for selected patients, but it requires careful eligibility assessment, close monitoring, and care from an experienced multidisciplinary team.

Overview

CAR T-cell therapy, also called chimeric antigen receptor T-cell therapy, is a type of cancer immunotherapy. It uses T cells, a key part of the immune system, to help find and attack cancer cells. In most approved uses, the patient’s own T cells are collected from the blood, changed in a specialized laboratory, and then returned to the body as a personalized treatment.

The word “chimeric” refers to the engineered receptor added to the T cell. This receptor is designed to recognize a specific marker, or antigen, on the surface of cancer cells. Once the modified T cells are infused back into the bloodstream, they can multiply, search for cells carrying that target, and help destroy them.

CAR T-cell therapy is not the same as standard chemotherapy, radiation therapy, or surgery. It is most often used for certain blood cancers when the disease has not responded well to previous treatments or has returned after treatment. It is a highly specialized therapy that requires planning, eligibility testing, and monitoring in a center experienced in cellular therapies.

How CAR T-Cell Therapy Works

The CAR T-cell therapy process begins with collecting T cells from the patient through a procedure called leukapheresis. During leukapheresis, blood is drawn through an intravenous line, the needed immune cells are separated, and the rest of the blood is returned to the patient. The collection usually does not require surgery, although the patient may need a special catheter if their veins are difficult to access.

After collection, the T cells are sent to a specialized laboratory. There, they are genetically modified so they can produce chimeric antigen receptors on their surface. These receptors act like guided recognition tools, helping the T cells attach to a chosen cancer-cell target, such as CD19 in some B-cell leukemias and lymphomas or BCMA in some cases of multiple myeloma.

While the cells are being prepared, the care team may use “bridging therapy” in some patients to keep the cancer under control. Before the CAR T cells are infused, patients typically receive a short course of chemotherapy called lymphodepleting chemotherapy. This is not given mainly to kill cancer directly; it helps create space in the immune system so the infused CAR T cells can expand and work more effectively.

The CAR T-cell infusion is usually given through a vein, similar to a blood transfusion. After the infusion, the medical team monitors the patient closely for early side effects and signs of response. Some effects can develop within days, while others may appear later, so follow-up appointments and blood tests are an important part of treatment.

Eligibility: Who May Be Considered

CAR T-cell therapy is generally considered for specific cancer types and situations. Approved indications vary by country and product, but the therapy is most commonly used for selected patients with relapsed or refractory blood cancers, including some types of acute lymphoblastic leukemia, large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, and multiple myeloma. “Relapsed” means the cancer has returned after treatment, while “refractory” means it has not responded adequately to treatment.

Eligibility depends on more than the cancer diagnosis alone. Doctors assess the exact cancer subtype, previous treatments, current disease burden, organ function, infection risk, blood counts, overall fitness, and ability to complete monitoring after infusion. The care team also considers whether the cancer cells carry the target antigen for the CAR T product being considered.

Common factors reviewed during evaluation include:

• The patient’s diagnosis, stage, and treatment history
• Whether the cancer has the appropriate target antigen
• Heart, lung, liver, kidney, and neurologic health
• Current infections or immune system weakness
• Performance status, frailty, and ability to tolerate possible side effects
• Practical needs, such as staying near the treatment center after infusion

CAR T-cell therapy is not suitable for every patient, and it is not currently a routine treatment for most solid tumors. Clinical trials continue to study whether CAR T-cell approaches can be used more widely. A hematologist, medical oncologist, or cellular therapy specialist can explain whether this option fits a patient’s diagnosis and goals of care.

What to Expect Before, During, and After Treatment

Before treatment, patients usually have a detailed assessment. This may include blood tests, imaging scans, heart and lung tests, infection screening, bone marrow evaluation when appropriate, and review of previous biopsy results. The team also reviews current medicines, allergies, vaccination history, and any history of seizures, stroke, autoimmune disease, or significant organ problems.

The time between cell collection and infusion can vary because the CAR T cells must be manufactured and quality-checked. During this period, patients may feel physically well or may need additional treatment to control symptoms. The care team gives individualized guidance about infection precautions, nutrition, activity, and when to report symptoms.

After infusion, patients are monitored closely, often in or near the hospital, depending on the center’s protocol and the patient’s risk. The first few weeks are especially important because side effects such as fever, low blood pressure, confusion, or low blood counts can develop. Many programs require a caregiver and advise patients to remain within a reasonable distance of the treatment center for a period after infusion.

Recovery varies. Some people feel fatigued for weeks, and blood counts may take time to improve. Follow-up visits help doctors assess response, manage side effects, screen for infections, and plan the next steps. Patients are usually advised not to drive or operate machinery for a period after treatment because neurologic side effects can occur even after discharge.

Possible Side Effects and Safety Monitoring

CAR T-cell therapy can be very active in the immune system, so side effects require careful monitoring. One of the best-known side effects is cytokine release syndrome, or CRS. CRS happens when activated immune cells release inflammatory signals called cytokines. It may cause fever, chills, tiredness, low blood pressure, fast heartbeat, low oxygen levels, or changes in organ function. Many cases are manageable with supportive care and specific medicines, but prompt recognition is important.

Another important side effect is immune effector cell-associated neurotoxicity syndrome, often shortened to ICANS. Neurologic symptoms can include headache, confusion, difficulty speaking, tremor, sleepiness, or, less commonly, seizures. The care team performs regular neurologic checks after infusion so that changes can be recognized early and treated according to established protocols.

Other possible side effects include low blood cell counts, increased infection risk, fatigue, nausea, reduced appetite, and electrolyte changes. Some patients may develop B-cell aplasia when the CAR T cells also affect healthy B cells that carry the same target as the cancer cells. This can lower antibody levels and may require infection prevention measures or immunoglobulin replacement in selected cases.

Longer-term follow-up is part of responsible care. Patients may need repeated blood tests, immune system monitoring, infection prevention advice, and guidance about revaccination when appropriate. Side effect management is individualized, and patients should never try to manage fever, confusion, breathing difficulty, or sudden weakness at home without contacting the treatment team.

Benefits, Limitations, and Treatment Goals

For selected patients with certain blood cancers, CAR T-cell therapy may offer a treatment option when standard therapies have not worked or have stopped working. The goal may be remission, longer disease control, symptom improvement, or creating another pathway in a complex treatment plan. The most realistic goal depends on the cancer type, prior treatments, response to previous therapy, and overall health.

At the same time, CAR T-cell therapy has limitations. It is not guaranteed to work, and some cancers do not respond or may return after an initial response. Cancer cells can sometimes reduce or lose the target antigen, or the modified T cells may not persist long enough. Researchers are studying ways to improve durability, reduce side effects, and expand treatment to more cancer types.

Decision-making should include a balanced discussion of benefits, risks, alternatives, and quality of life. Alternatives may include targeted therapy, antibody therapy, stem cell transplant, chemotherapy, radiation therapy, clinical trials, or supportive and palliative care, depending on the situation. A second opinion from a cellular therapy center can be helpful when the decision is complex.

Prevention, Self-Care, and When to See a Doctor

CAR T-cell therapy is a treatment rather than a prevention method, so there is no lifestyle change that can make a patient eligible or replace specialist cancer care. However, good self-care before and after treatment can support recovery. Patients are generally encouraged to follow nutrition guidance, stay as active as their condition allows, protect themselves from infections, take medicines exactly as prescribed, and attend all scheduled follow-up appointments.

Patients and caregivers should know which symptoms require urgent contact with the treatment team. These commonly include fever, chills, shortness of breath, dizziness, confusion, difficulty speaking, severe headache, seizure, unusual bleeding, persistent vomiting, reduced urination, or any sudden change in alertness or strength. Because the immune system can remain weakened, even mild symptoms may need medical advice after CAR T-cell therapy.

A doctor should be consulted if a patient has a relapsed or refractory blood cancer and wants to know whether CAR T-cell therapy is an option. The discussion is especially relevant when standard treatments are no longer controlling the disease or when a hematologist has mentioned cellular therapy. Early referral can be useful because eligibility assessment, insurance or authorization processes, donor and transplant history review, and cell manufacturing all take time.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat cancer, including advanced hematology and oncology cases, for international patients. For any patient considering CAR T-cell therapy, the safest next step is a personalized evaluation by a qualified oncology team experienced in cellular therapies.

Frequently asked questions

What cancers can CAR T-cell therapy treat?

CAR T-cell therapy is mainly used for selected blood cancers, such as certain leukemias, lymphomas, and multiple myeloma. The exact approved uses depend on the country, the CAR T product, the cancer subtype, and previous treatments. It is not currently a standard treatment for most solid tumors.

Is CAR T-cell therapy chemotherapy?

CAR T-cell therapy is not traditional chemotherapy. It is an immunotherapy that modifies a patient’s T cells to better recognize cancer cells. However, patients usually receive a short course of lymphodepleting chemotherapy before the CAR T infusion to help the modified cells work effectively.

How long does CAR T-cell therapy take?

The full process usually takes several weeks, because cells must be collected, engineered in a laboratory, tested, and returned for infusion. Some patients may need treatment during this waiting period to keep the cancer controlled. After infusion, close monitoring continues for weeks, with longer-term follow-up over months and years.

What is cytokine release syndrome?

Cytokine release syndrome, or CRS, is an immune reaction that can happen after CAR T-cell therapy. It may cause fever, chills, low blood pressure, breathing symptoms, or changes in organ function. Treatment teams monitor for CRS closely and use established medicines and supportive care when needed.

Can older adults receive CAR T-cell therapy?

Age alone does not automatically exclude a patient from CAR T-cell therapy. Doctors look at overall fitness, organ function, cancer status, infection risk, and the ability to tolerate possible side effects. Some older adults may be suitable, while others may be better served by different treatment options.

Does CAR T-cell therapy cure cancer?

CAR T-cell therapy can lead to deep and lasting remissions in some patients, but it does not guarantee a cure. Some cancers do not respond, and some return after an initial response. A specialist can explain the likely goals and expectations for a specific diagnosis.

Why is follow-up important after CAR T-cell therapy?

Follow-up is essential because side effects can appear after infusion and the immune system may remain weakened for some time. Doctors monitor blood counts, infection risk, neurologic symptoms, and the cancer’s response to treatment. Follow-up also helps guide vaccinations, supportive care, and any additional treatment decisions.

References

• National Cancer Institute
• American Society of Clinical Oncology
• European Society for Medical Oncology
• U.S. Food and Drug Administration
• European Medicines Agency

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.